Herbert Irving Comprehensive Cancer Center, Columbia University
Columbia's NCI comprehensive cancer centre, strong in lymphoma genetics, systems biology of cancer and the discovery of ferroptosis.
NCI-designated since 1972, the Herbert Irving Comprehensive Cancer Center is the cancer centre of Columbia University Irving Medical Center and NewYork-Presbyterian in Upper Manhattan. Riccardo Dalla-Favera defined BCL6 and the genetic lesions of B-cell lymphoma; Andrea Califano's systems biology of master regulators spun out DarwinHealth; Brent Stockwell discovered and named ferroptosis in 2012; Adolfo Ferrando dissected T-cell acute lymphoblastic leukaemia. Dawn Hershman leads SWOG's cancer care delivery research from here, and Siddhartha Mukherjee, author of The Emperor of All Maladies, runs a leukaemia laboratory. Director Anil Rustgi is a GI cancer biologist.
- Lymphoma and leukaemia genetics
- Systems biology
- Ferroptosis
- Cancer care delivery (SWOG)
Pages like this
not linked directly; found by shared links- PersonMariana Chavez-MacGregor
Shares SWOG Cancer Research Network, HR-positive / HER2-negative breast cancer.
- InstitutionTata Medical Center, Kolkata
Shares Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- InstitutionNational Cancer Institute, Cairo University
Shares Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- InstitutionKing Faisal Specialist Hospital and Research Centre
Shares Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- InstitutionKing Hussein Cancer Center
Shares Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, HR-positive / HER2-negative breast cancer.
- PersonPrimo N. Lara Jr.
- InstitutionInstituto Nacional de Câncer (INCA)
Shares Acute lymphoblastic leukaemia, Prostate cancer, HR-positive / HER2-negative breast cancer.
- InstitutionKenyatta National Hospital
Shares Diffuse large B-cell lymphoma, Prostate cancer, HR-positive / HER2-negative breast cancer.